

The exercise period for Prostatype Genomics' warrants of series TO 4 commences today

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE MEASURES OTHER THAN THOSE REQUIRED UNDER SWEDISH LAW. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Today is the first day for the exercise period of Prostatype Genomics AB's ("Prostatype" or "Company") warrants of series TO 4 ("TO 4") which were issued in connection with the rights issue of units carried out by the Company earlier this year. The exercise period lasts until 9 December 2024. Terms for exercising TO 4 after adjustment following the reverse split of Prostatype's share on October 31, is that a thousand (1,000) warrants of series TO 4 grant the holder the right to subscribe for one (1) new share in Prostatype at a price of SEK 5.96 per share. At full subscription of TO 4, the Company can receive a maximum of approximately SEK 9.9 million before issue costs. An information folder established in connection for the TO 4 exercise is available as an attachment to this press release and on Prostatype's (www.prostatypegenomics.com) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites.

In August 2024, Prostatype carried out a rights issue which provided the Company with approximately SEK 35.7 million before issue costs. Through the rights issue and subsequent directed issue to guarantors, a total of 1,663,016,092 warrants of series TO 4 were issued. Terms for exercising warrants, after adjustment due to the Company's reverse share split on October 31, 2024, are that a thousand (1,000) warrants of series TO 4 grant the right to subscribe for one (1) new share in Prostatype during the exercise period, which runs from 25 November to 9 December 2024. The subscription price for TO 4 has been set at 5.96 SEK per share, corresponding to 70 percent of the volume-weighted average price of the Company's share during the period 11 to 22 November 2024. If all warrants of series TO 4 are fully exercised, the Company will receive approximately 9.9 million SEK before issuance costs.

TO 4 in short

- One thousand (1000) TO 4 grants the warrant holder the right to subscribe for one (1) new share in Prostatype at a price of SEK 5.96 per share.
- There are 1,663,016,092 issued warrants of series TO 4. At full subscription of TO 4, Prostatype receives approx. SEK 9.9 million before issue costs.
- Number of outstanding shares prior to warrant exercise: 5,148,351 shares.
- TO 4 are traded at First North Stockholm under short name "PROGEN TO4" and with ISIN SE0022574554. Last day of trading in TO 4 is 5 December 2024.

Complete terms and instructions for warrants of series TO 4 are available on the Company's website (www.prostatypegenomics.com). An information folder containing summary information about the warrant exercise is available as an attachment to this press release and on Prostatype's and Nordic Issuing AB's (www.nordic-issuing.se) respective websites during the exercise period.

Important dates

- 5 December 2024: Last day of trading in TO 4.
- 9 December 2024: Exercise period ends.
- 10 December 2024: Preliminary date for announcement of outcome of the exercise.
- 20 December 2024: Preliminary date for conversion from interim shares to ordinary shares.

Shares and share capital

Upon full utilization of TO 4, the number of shares in Prostatype will increase by 1,663,016 shares to a total of 6,811,367 shares and the share capital will increase by SEK 166,301,60 to SEK 681,136.70. The dilution at full utilization amounts to approximately 24.4 percent of the capital and votes.

Advisors

In connection with the warrant exercise, Prostatype has engaged Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the Company, please contact:

Fredrik Rickman, CEO

Tel: +46 (0)73-049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com

About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important Information

This press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, unit rights, BTUs, or other securities in Prostatype Genomics AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the commencement of the subscription period in the Rights Issue. No action has been or will be taken to allow a public offering in any jurisdictions other than Sweden.

This press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus, or any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants, subscription rights, BTUs, or other securities to any person in a jurisdiction where such an offer would be unlawful or would require prospectuses, additional registration, or other

measures beyond those required by Swedish law. The prospectus and other documents related to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires actions as mentioned above or where it would conflict with the regulations of such country. Any actions in violation of these instructions may constitute a breach of applicable securities laws.

No shares, warrants, unit rights, BTUs, or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements reflecting the Company's current views on future events as well as financial and operational developments. Words such as "intends," "assesses," "expects," "may," "plans," "believes," "estimates," and other expressions indicating or predicting future developments or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with both known and unknown risks and uncertainties, as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from what is expressed in the forward-looking statements. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revisions of any forward-looking statements to reflect events that occur or circumstances that arise with regard to the content of this press release, unless required by law or the Nasdaq First North Growth Market's regulations.

Attachments

[T04 Informationsfolder 241125](#)